

EQA round: APLA1/24 - Antiphospholipid Antibodies

Deadline: 15.3.2024

Setup: Slovakia

AV = assigned value

CVP = consensus of all participants

>>> ... expected result

> ... acceptable result

± ... result not assessed

N_{tot} = total number of the resultsN_{rel} = relative number of the resultsN_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
(465) anti-β2-glycoprotein 1 screening		5				5	5	100
Sample A		5				5	5	100
All results	CVP >>>	5	100	Negative				
Sample B		5				5	5	100
All results	CVP >>>	5	100	Positive				
(467) anti-β2-glycoprotein 1 IgG		12				12	11	92
Sample A		12				12	12	100
All results	CVP >>>	12	100	Negative				
Sample B		12				12	11	92
All results		1	8,3	Negative				
	CVP >>>	11	92	Positive				
(468) anti-β2-glycoprotein 1 IgM		12				12	11	92
Sample A		12				12	12	100
All results	CVP >>>	12	100	Negative				
Sample B		12				12	11	92
All results		1	8,3	Negative				
	CVP >>>	11	92	Positive				
(461) anti-cardiolipin screening		6				6	6	100
Sample A		6				6	6	100
All results	CVP >>>	6	100	Negative				
Sample B		6				6	6	100
All results	CVP >>>	6	100	Positive				
(463) anti-cardiolipin IgG		12				12	12	100
Sample A		12				12	12	100
All results	CVP >>>	12	100	Negative				
Sample B		12				12	12	100
All results		>	1	8,3	Negative			
	CVP >>>	11	92	Positive				
(464) anti-cardiolipin IgM		12				12	12	100
Sample A		12				12	12	100
All results	CVP >>>	12	100	Negative				
Sample B		12				12	12	100
All results	CVP >>>	12	100	Positive				